Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.

An overview of how HMAs are being used to treat CMML and their use in combination with other therapies for patients with AML.

An expert discusses data supporting the use of HMAs in the treatment of lower-risk MDS.

A review of the benefits of oral HMA treatments in the management of MDS, and the impact on a patient's quality of life.

An expert discusses the real-world impact of hypomethylating agents for the treatment of patients with MDS.

Guillermo Garcia-Manero, MD, provides a high-level overview of the effectiveness of oral HMA agents in the treatment of intermediate- and high-risk MDS.

The role of HMAs in the treatment of patients with intermediate- and high-risk MDS.

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). In this episode, gain insights about MDS risk stratification and prognosis, and why it is important to treat early.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.

Guillermo Garcia-Manero, MD, reviews data from the COMMANDS trial comparing the efficacy and safety of luspatercept to epoetin alfa in patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on blood transfusions and have not previously received erythropoiesis-stimulating agents (ESAs).